Cel­gene vet Daniel takes a start­up role at Vi­vid­ion, with $50M in hand for plat­form con­struc­tion

You can count Tom Daniel as the lat­est big bio­phar­ma ex­ec to make the tran­si­tion to biotech.

The Cel­gene vet­er­an has tak­en on the ex­ec­u­tive chair­man’s po­si­tion at a start­up called Vi­vid­ion Ther­a­peu­tics, which has col­lect­ed $50 mil­lion in a round led by Arch and Ver­sant. And he is tak­ing a lead­ing role in cre­at­ing a new com­pa­ny that has fash­ioned a brand new plat­form tech­nol­o­gy out of the lab of Scripps re­searcher Ben Cra­vatt.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER